Reduced side effects and more effective therapies are some of the benefits promised by pharmacogenomics. But to reach these goals industry will have to marshall a broad range of skills, as Ricki Lewis explains.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Author notes
Ricki Lewis is a freelance writer in Scotia, New York.
- Ricki Lewis
Related links
Related links
Related links in Nature Research
Pharmacogenetics initiative galvanizes public and private sectors
Related external links
FDA pharmacogenomics guidelines
Rights and permissions
About this article
Cite this article
Lewis, R. An individual approach. Nature 436, 746–747 (2005). https://doi.org/10.1038/nj7051-746a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7051-746a
